Product Type
Fc Silent Antibody
Description
The Fc-mediated effector functions of antibodies include antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC), and have been shown to be crucial for the therapeutic efficacy of most clinically approved antibodies. However, engaging immune effectors through FcγR and complement interactions may be detrimental to certain mAb mechanisms of action and so Fc-null or -silenced antibodies may be desired.
Creative Biolabs uses site-directed mutagenesis technology to generate Fc-silenced antibody with reduced effector functions. The mutated Fc domains eliminate the binding of Fc receptors (FcγR, FcR), thereby leading to a significant reduction in ADCC and CDC in comparison to WT IgG.
Immunogen
hA33 was generated by humanization of mouse A33 IgG2a-κ by CDR-grafting, and expressed in NSO cells. The mouse A33 antibody was prepared by immunizing BALB/c mice with AsPC-1 pancreatic adenocarcin...
Species
Human
Cross reactivity
Human
Clonality
Monoclonal
Clone Number
huA33
Conjugation
Unconjugated
Buffer
PBS only
Application
Depl, EL, IF, IHC
Storage Instructions
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Official Name
ADAMTS13
Alternative Names
ADAMTS13, ADAM-TS13, ADAMTS-13, C9orf8, VWFCP, vWF-CP, ADAM metallopeptidase with thrombospondin type 1 motif 13
